210 related articles for article (PubMed ID: 32130471)
1. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
[TBL] [Abstract][Full Text] [Related]
2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
3. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.
Park S; Lee SJ; Jung CW; Jang JH; Kim SJ; Kim WS; Kim K
Ann Hematol; 2014 Jan; 93(1):99-105. PubMed ID: 24240976
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
5. DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma.
Yuen HLA; Low MSY; Fedele P; Kalff A; Walker P; Bergin K; Coutsouvelis J; Grigoriadis G; Spencer A
Leuk Lymphoma; 2018 Dec; 59(12):2842-2846. PubMed ID: 29616871
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Siegel DS; Schiller GJ; Song KW; Agajanian R; Stockerl-Goldstein K; Kaya H; Sebag M; Samaras C; Malek E; Talamo G; Seet CS; Mouro J; Pierceall WE; Zafar F; Chung W; Srinivasan S; Agarwal A; Bahlis NJ
Br J Haematol; 2020 Feb; 188(4):501-510. PubMed ID: 31588567
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.
Byun JM; Min CK; Kim K; Bang SM; Lee JJ; Kim JS; Yoon SS; Koh Y
J Hematol Oncol; 2022 Oct; 15(1):150. PubMed ID: 36274163
[TBL] [Abstract][Full Text] [Related]
10. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
11. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.
Lazzarino M; Corso A; Barbarano L; Alessandrino EP; Cairoli R; Pinotti G; Ucci G; Uziel L; Rodeghiero F; Fava S; Ferrari D; Fiumanò M; Frigerio G; Isa L; Luraschi A; Montanara S; Morandi S; Perego D; Santagostino A; Savarè M; Vismara A; Morra E
Bone Marrow Transplant; 2001 Nov; 28(9):835-9. PubMed ID: 11781643
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
14. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Gerrie AS; Mikhael JR; Cheng L; Jiang H; Kukreti V; Panzarella T; Reece D; Stewart KA; Trieu Y; Trudel S; Chen CI
Br J Haematol; 2013 Jun; 161(6):802-10. PubMed ID: 23594335
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Baz RC; Martin TG; Lin HY; Zhao X; Shain KH; Cho HJ; Wolf JL; Mahindra A; Chari A; Sullivan DM; Nardelli LA; Lau K; Alsina M; Jagannath S
Blood; 2016 May; 127(21):2561-8. PubMed ID: 26932802
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
17. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
18. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
Stöhr E; Schmeel FC; Schmeel LC; Hänel M; Schmidt-Wolf IG;
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2205-12. PubMed ID: 26156122
[TBL] [Abstract][Full Text] [Related]
20. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Venner CP; LeBlanc R; Sandhu I; White D; Belch AR; Reece DE; Chen C; Dolan S; Lalancette M; Louzada M; Kew A; McCurdy A; Monteith B; Reiman T; McDonald G; Sherry M; Gul E; Chen BE; Hay AE
Am J Hematol; 2021 May; 96(5):552-560. PubMed ID: 33650179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
